An analysis by a United Nations monitoring body concludes that most of the World Health Organization’s (WHO) cannabis scheduling recommendations would either have little impact on international drug controls or actually tighten requirements.
The United Kingdom has down-scheduled Epidyolex to the lowest level of control for drugs, greatly easing restrictions on the cannabidiol medicine and reducing administrative processes for companies wanting to supply it.
England’s medical cannabis market has barely gotten off the ground since launching about 19 months ago, with a two-tier system in which few patients access products through legal channels while most resort to illicit suppliers.
Brazil’s health authorities authorized the first medical cannabis product registered under rules created in December 2019, marking an important milestone for the industry in Latin America’s largest economy.
Doctors in New Zealand no longer require Ministry of Health approval to prescribe Sativex, according to a new notice published in the country’s official Gazette – a move that could facilitate access to the pharmaceutical-grade, cannabis-based product.
European Union Good Manufacturing Practice (EU-GMP) certification audits involving cannabis facilities in Canada and elsewhere are screeching to a halt given the travel restrictions in place in most of the world because of the coronavirus pandemic.
